Head-To-Head Review: GoodRx (NASDAQ:GDRX) & Biocorrx (OTCMKTS:BICX)

GoodRx (NASDAQ:GDRX) and Biocorrx (OTCMKTS:BICX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Volatility & Risk

GoodRx has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Institutional & Insider Ownership

63.8% of GoodRx shares are owned by institutional investors. 4.5% of GoodRx shares are owned by insiders. Comparatively, 21.4% of Biocorrx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares GoodRx and Biocorrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GoodRx	3.82%	9.31%	4.38%
Biocorrx	N/A	N/A	-96.39%

Earnings & Valuation

This table compares GoodRx and Biocorrx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85 million	0.86	$30.44 million	$0.09	22.56
Biocorrx	$10,000.00	1,056.00	-$5.11 million	($0.32)	-1.25

GoodRx has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for GoodRx and Biocorrx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3	8	5	0	2.13
Biocorrx	0	1	0	0	2.00

GoodRx presently has a consensus price target of $3.98, suggesting a potential upside of 96.10%. Given GoodRx’s stronger consensus rating and higher possible upside, equities analysts clearly believe GoodRx is more favorable than Biocorrx.

Summary

GoodRx beats Biocorrx on 12 of the 14 factors compared between the two stocks.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.